<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790308</url>
  </required_header>
  <id_info>
    <org_study_id>13450149260</org_study_id>
    <nct_id>NCT01790308</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function</brief_title>
  <official_title>Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and evaluate the effects of liraglutide combined
      with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control
      and β-cell function in newly diagnosed type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate and evaluate the effects of liraglutide combined
      with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.liraglutide
      combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed
      type 2 diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the percentage of the patients who maintain glucose control 1 year after short intensive therapy</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the acute insulin response reflected β-cell function of different interventions in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuous subcutaneous insulin infusion for 2-4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII</intervention_name>
    <description>continuous subcutaneous insulin infusion for 2~4 weeks</description>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed type 2 diabetes

          -  fasting blood glucose (FBG) level ranging from 7.0-16.7mmol/L

          -  body mass index (BMI) ranging from 21-35kg/m2

          -  antihypercaemic and antihyperlipidemic medication-naive patients

        Exclusion Criteria:

          -  having any severe acute or chronic diabetic complications

          -  renal dysfunction, blood creatinine&gt;150umol/L

          -  blood aminotransferase level rising up(more than 2 times of the upper normal limit of
             ALT)

          -  any severe cardiac disease including congestive cardiac failure, unstable angina or
             myocardial infarct in 12 months

          -  chronic or acute pancreatic disease

          -  severe systemic diseases or malignant tumor

          -  female patients incline to be pregnant

          -  being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs

          -  poor compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanbing Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Education</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 11, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanbing Li</investigator_full_name>
    <investigator_title>director of the endocrinology department of the First Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
